Select Page

The M-POWER project is partnering with cities across the country to turn the core vision of the IMF Diversity Initiative into a reality: improving the short- and long-term outcomes of African-American patients with multiple myeloma.

Multiple myeloma is the most common blood cancer in African Americans, who have a greater-than-average risk of developing the disease. But when barriers to early diagnosis and treatment are removed, African-American myeloma patients do just as well, or even better than, white individuals.

M-POWER is empowering health-care professionals, community leaders, neighborhoods and families to break down those barriers by raising myeloma awareness. 


of all cases of myeloma are in African Americans

more common in African Americans


of all newly diagnosed myeloma patients will be African American

Multiple Myeloma

Did you know that myeloma is the most common blood cancer in people of African descent? But doctors do not typically check people for myeloma during a regular visit because currently there are no national screening recommendations for myeloma.

That’s why it’s important to learn the early symptoms of myeloma and let your doctor know that you—or a friend or family member—are at added risk for the disease.

Because even though myeloma affects African Americans at greater rates, with early diagnosis and treatment, African Americans can have better overall survival in living with the disease.

Myeloma Tool Kit

Disparities in Myeloma Made Simple!

Join Dr. Joseph Mikhael as he explores the inequities in healthcare faced by socially disadvantaged populations, particularly African American patients with multiple myeloma. Discover the factors contributing to these disparities and learn about the International Myeloma Foundation’s commitment to improving outcomes through the M-Power program.

Abstracts on racial disparities in myeloma care

IMF Chief Medical Officer Dr. Joseph Mikhael (TGen, City of Hope — Phoenix) talks about abstracts on racial disparities in myeloma care as reported from this year’s American Society of Hematology (ASH) annual conference held in Atlanta, GA. 

Atlanta Community Workshop

Learn about multiple myeloma, a disease more than twice as common in people of African descent as in whites. From “Myeloma for Patients Who Are Just Getting Started” to the latest in treatments and research, this comprehensive program also features a myeloma patient’s story and an opportunity for the audience to ask questions.

with support from:

2seventy bio, Amgen, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Pfizer, Oncopeptides, Sanofi Genzyme, Takeda Oncology, The Binding Site 

A Day in the Life

The “A Day in the Life” podcast from the International Myeloma Foundation features messages of hope and resilience for myeloma patients, caregivers, and their loved ones. Today we’re talking to Jameca Barret, a myeloma patient who helped start the South Side Myeloma Support Group in Atlanta and has been an advocate for herself and for others in the myeloma community for many years.

Disparities in Treatment

My experiences over the years as a support group leader have been that most leaders are experiencing similar challenges, looking for ways to diversify group participation and ensure that we all live well with myeloma. Much like the health-care system, we have to better understand barriers to participation.

- Tiffany Williams

Diagnosed with myeloma in 2013, Tiffany is a co-facilitator of the Charleston, South Carolina Area Multiple Myeloma Networking Group

Patient advocate Yelak Biru shares his story

Diagnosed at the young age of 25 with stage III multiple myeloma, Yelak Biru is a patient turned myeloma research advocate. Working with a team of medical practitioners and educating himself through support group leadership, information resources, advocacy sites, social media, and the IMF, Yelak has successfully integrated myeloma to his life for over two decades.

We want to hear from you: